MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 565260 | Name: BV02
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BV02 is an inhibitor of SFN. It also targets YWHAZ of the 14-3-3 protein family.

Chemical Structure

BV02
BV02
CAS#292870-53-2

Theoretical Analysis

MedKoo Cat#: 565260

Name: BV02

CAS#: 292870-53-2

Chemical Formula: C20H15N3O5

Exact Mass: 377.1012

Molecular Weight: 377.36

Elemental Analysis: C, 63.66; H, 4.01; N, 11.14; O, 21.20

Price and Availability

Size Price Availability Quantity
5mg USD 275.00 2 Weeks
25mg USD 655.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
BV 02; BV 02; BV02
IUPAC/Chemical Name
2-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1,3-dioxoisoindoline-5-carboxylic acid
InChi Key
ZFYSDSINNOLWGO-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H15N3O5/c1-11-16(19(26)23(21(11)2)13-6-4-3-5-7-13)22-17(24)14-9-8-12(20(27)28)10-15(14)18(22)25/h3-10H,1-2H3,(H,27,28)
SMILES Code
O=C1N(C2=CC=CC=C2)N(C)C(C)=C1N3C(C(C=C(C(O)=O)C=C4)=C4C3=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 377.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Iralde-Lorente L, Cau Y, Clementi L, Franci L, Tassone G, Valensin D, Mori M, Angelucci A, Chiariello M, Botta M. Chemically stable inhibitors of 14-3-3 protein-protein interactions derived from BV02. J Enzyme Inhib Med Chem. 2019 Dec;34(1):657-664. doi: 10.1080/14756366.2019.1574779. PubMed PMID: 30727786. 2: Root A, Beizaei A, Ebhardt HA. Structure-based assessment and network analysis of targeting 14-3-3 proteins in prostate cancer. Mol Cancer. 2018 Oct 31;17(1):156. doi: 10.1186/s12943-018-0905-y. PubMed PMID: 30382885; PubMed Central PMCID: PMC6208026. 3: Kim SW, Md Hasanuzzaman, Cho M, Kim NH, Choi HY, Han JW, Park HJ, Oh JW, Shin JG. Role of 14-3-3 sigma in over-expression of P-gp by rifampin and paclitaxel stimulation through interaction with PXR. Cell Signal. 2017 Feb;31:124-134. doi: 10.1016/j.cellsig.2017.01.001. Epub 2017 Jan 7. PubMed PMID: 28077325. 4: Kim HJ, Lee SY, Kim CY, Kim YH, Ju W, Kim SC. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells. Oncotarget. 2017 Jan 24;8(4):6608-6622. doi: 10.18632/oncotarget.14245. PubMed PMID: 28036259; PubMed Central PMCID: PMC5351656. 5: Fernández-Orth J, Ehling P, Ruck T, Pankratz S, Hofmann MS, Landgraf P, Dieterich DC, Smalla KH, Kähne T, Seebohm G, Budde T, Wiendl H, Bittner S, Meuth SG. 14-3-3 Proteins regulate K(2P) 5.1 surface expression on T lymphocytes. Traffic. 2017 Jan;18(1):29-43. doi: 10.1111/tra.12455. Epub 2016 Nov 27. PubMed PMID: 27743426. 6: Gómez-Suárez M, Gutiérrez-Martínez IZ, Hernández-Trejo JA, Hernández-Ruiz M, Suárez-Pérez D, Candelario A, Kamekura R, Medina-Contreras O, Schnoor M, Ortiz-Navarrete V, Villegas-Sepúlveda N, Parkos C, Nusrat A, Nava P. 14-3-3 Proteins regulate Akt Thr308 phosphorylation in intestinal epithelial cells. Cell Death Differ. 2016 Jun;23(6):1060-72. doi: 10.1038/cdd.2015.163. Epub 2016 Feb 5. PubMed PMID: 26846144; PubMed Central PMCID: PMC4987727. 7: Valensin D, Cau Y, Calandro P, Vignaroli G, Dello Iacono L, Chiariello M, Mori M, Botta M. Molecular insights to the bioactive form of BV02, a reference inhibitor of 14-3-3σ protein-protein interactions. Bioorg Med Chem Lett. 2016 Feb 1;26(3):894-898. doi: 10.1016/j.bmcl.2015.12.066. Epub 2015 Dec 21. PubMed PMID: 26774582. 8: Musafia B, Oren-Banaroya R, Noiman S. Designing anti-influenza aptamers: novel quantitative structure activity relationship approach gives insights into aptamer-virus interaction. PLoS One. 2014 May 20;9(5):e97696. doi: 10.1371/journal.pone.0097696. eCollection 2014. PubMed PMID: 24846127; PubMed Central PMCID: PMC4028238. 9: Mohammad DK, Nore BF, Hussain A, Gustafsson MO, Mohamed AJ, Smith CI. Dual phosphorylation of Btk by Akt/protein kinase b provides docking for 14-3-3ζ, regulates shuttling, and attenuates both tonic and induced signaling in B cells. Mol Cell Biol. 2013 Aug;33(16):3214-26. doi: 10.1128/MCB.00247-13. Epub 2013 Jun 10. PubMed PMID: 23754751; PubMed Central PMCID: PMC3753922. 10: Mancini M, Corradi V, Petta S, Barbieri E, Manetti F, Botta M, Santucci MA. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib. J Pharmacol Exp Ther. 2011 Mar;336(3):596-604. doi: 10.1124/jpet.110.172536. Epub 2010 Nov 1. PubMed PMID: 21041536.